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a EgyptObjectives: To investigate the different clinical and echocardiographic predictors of evolving PH in patients with
heart failure with and without reduced ejection fraction.
Methods and Results: The study included 153 heart failure patients with reduced ejection fraction (HFrEF) (n = 89)
and preserved ejection fraction (HFpEF) (n = 64) both of which were subdivided into 2 subgroups according to the
presence of PH. All patients were subjected to detailed clinical assessment and full transthoracic echocardiogram.
There were significant differences between the 2 HFrEF subgroups regarding systolic BP, presence of diabetes, dys-
lipidemia, diuretics usage, all LV parameters, LAD, LAV and LAV indexed to BSA, E/A ratio, DT and severity of TR.
Using multivariate analysis, the presence of diabetes (P = 0.04), diuretics usage (P = 0.04), LAV (P = 0.007) and TR
grade (P < 0.001) were significant independent predictors for the development of PH among HFrEF patients. There
were significant differences between the 2 HFpEF subgroups regarding presence of hypertension, diuretics usage,
LAD, LAA, TR severity. Using multivariate analysis, only diuretics usage (P = 0.02) and TR grade (P < 0.0001) were
significant independent predictors for the development of PH among HFpEF patients.
Conclusion: Neither the decrease in EF among HFrEF patients nor the DD grade in HFpEF patients act as indepen-
dent predictor for evolving PH. Common independent predictors for evolving PH in both HFrEF and HFpEF patients
are TR grade and use of diuretics. Other independent predictors in HFrEF and not HFpEF patients are the presence
of diabetes and increased LAV.
 2016 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Pulmonary hypertension (PH) due to left heartdisease, classified as Group 2 according to
the Dana Point 2008 classification, is believed tobe the most common cause of PH and is associ-
ated with high morbidity and mortality [1].
Although initial studies suggested that reduced
left ventricular (LV) ejection fraction (EF) is the
main cause of PH, more recent studies could
establish an association between PH and diastolicNC-ND
re with
Abbreviations
DT deceleration time
EF ejection fraction
HF heart failure
HFrEF heart failure reduced ejection fraction
HFpEF heart failure preserved ejection fraction
LAA left atrial area
LAAP left atrial anteroposterior dimension
LAV left atrial volume
LAVEF left atrial volume emptying fraction
LV left ventricle
PASP pulmonary artery systolic pressure
PH pulmonary hypertension
RAP right atrial pressure
TR tricuspid regurgitation
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prognosis in these patients [2]. It was also shown
that PH depends on the severity of mitral regurgi-
tation as well as left atrial (LA) function [3].
Improved understanding of the different predic-
tors of development of PH in heart failure (HF)
patients with and without reduced function is
essential to determine an effective follow-up and
treatment strategies to reduce morbidity and mor-
tality in these patients. We sought to study differ-
ent clinical and noninvasive echocardiographic
parameters in patients with HF with and without
reduced LV functions to determine the indepen-
dent predictors of early PH in these patients and
whether they differ between HF patients with
reduced EF (HFrEF) and HF patients with pre-
served EF (HFpEF) or not.2. Methods
This study complies with the Declaration of Hel-
sinki and was approved by the institutional review
board of the Faculty of Medicine Ain Shams
University (Cairo, Egypt), and informed consent
was obtained from all enrolled patients.
2.1. Study population
This was a prospective observational study that
included all HF patients with and without reduced
EF referred for an elective transthoracic echocar-
diogram in the Cardiology Department Ain
Shams University Hospital in the period from
June 2015 to December 2015. The study included
a total of 153 patients who were subdivided into
two groups; Group 1 included HFrEF patients
(n = 89) and Group 2 included HFpEF patients
(n = 64). A cut-off point for EF of P50% was used
to differentiate between the two groups [4,5].
We excluded patients with: atrial fibrillation;
significant valvular heart disease; chronic obstruc-
tive pulmonary disease; primary PH or secondary
PH due to causes other than left-sided heart dis-
ease; and acute decompensated or Stage D HF [6].
2.2. Clinical assessment
All patients were clinically assessed for risk fac-
tors, typical signs and symptoms of HF and
antifailure medications [4]. Also the stage of HF
was determined. Drugs recorded included
digoxin, b-blockers, angiotensin converting
enzyme inhibitors, angiotensin receptor blockers,
and diuretics. Other medications used were listed
as others and were considered irrelevant in the
final statistical analysis as they were not pre-
scribed to sufficient number of patients to allowPlease cite this article in press as: Roushdy A., Adel W., Independent pr
reduced versus preserved ejection fraction, J Saudi Heart Assoc (2016), httfor relevant comparisons. The use of any of these
medications in the full therapeutic dose for the
last 6 months prior to the study was considered
positive to consider a patient receiving such a
medication.
2.3. Transthoracic echocardiogram
All patients were studied in the left lateral decu-
bitus position using an ultrasound system (Vivid
9; GE Healthcare, Chalfont-St Giles, Bucking-
hamshire, UK). Standard two-dimensional and
M-mode echocardiograms were obtained accord-
ing to the American Society of Echocardiography
guidelines. LV measurements included LV wall
thickness, internal dimensions, end-diastolic and
end-systolic volumes, EF by M mode, and modi-
fied Simpson’s rule.
LA size and function were assessed as follows
[7]:
 LA anteroposterior dimension (LAD): was
recorded from the standard parasternal short
axis view at the level of the aorta from the edge
of the posterior aortic wall to the LA edge at end
systole.
 LA area (LAA): was traced at end systole just
before opening of mitral valve by tracing the
LA inner border, excluding the area under the
mitral valve annulus and the inlet of the pul-
monary veins.
 LA volume (LAV): was obtained using the
biplane area–length formula of [0.85  (LAA in
apical four chamber view)  (LAA in the apical
two chamber view)]/shortest length from the
mitral annulus mid-plane to the superior bor-
der of the LA in the four- and two-chamber
views.
 LAV emptying fraction: The maximum and
minimum LA volumes were calculated from
the four-chamber view using Simpson’sedictors of developing pulmonary hypertension in heart failure with
p://dx.doi.org/10.1016/j.jsha.2016.10.005
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Table 1. Clinical and demographic characteristics of the study groups.
Characteristics Group 1 (HFrEF patients) Group 2 (HFpEF patients)
1A
Normal
PASP
n = 30
1B
PH
n = 59
p 2A
Normal
PASP
n = 31
2B
PH
n = 33
p
Sex (M/F) 21/9 42/17 0.757 26/5 27/6 0.826
Age (y) 59.5 ± 6.9 59.3 ± 7.2 0.226 57.35 ± 9.4 56.0 ± 3.25 0.491
Weight (kg) 79.8 ± 7.1 82.0 ± 6.9 0.137 80.8 ± 7.5 80.0 ± 5.13 0.745
BSA (m2) 1.9 ± 0.1 1.9 ± 0.09 0.035* 1.91 ± 0.08 1.94 ± 0.07 0.354
SBP (mmHg) 123.15 ± 16.3 114.6 ± 14.7 0.238 121.9 ± 13.8 126.3 ± 14.3 0.370
DBP (mmHg) 72.6 ± 13.3 68.4 ± 13.2 0.951 71.3 ± 10.56 77.3 ± 13.5 0.141
Risk factors for heart failure
Diabetes 16 (53.3%) 48 (81.3%) 0.04* 12 (38.8%) 21 (63.6%) 0.282
Dyslipidemia 15 (16.6%) 26 (44.1%) 0.005* 11 (35.5%) 6 (18.2%) 0.492
Hypertension 22 (73.3%) 41 (69.5%) 0.128 20 (64.5%) 30 (90.9%) 0.020
Obesity 11 (36.6%) 26 (44.0%) 0.521 9 (29.03%) 6 (18.2%) 0.761
Drug history
Digoxin 0 (0%) 11 (18.6%) 0.080 0 (0%) 0 (0%) –
ARBs/ACEi 30 (100%) 59 (100%) – 20 (64.5%) 27 (81.8%) 0.222
Diuretics 17 (56.6%) 56 (94.9%) 0.003* 7 (22.5%) 24 (72.7%) 0.009*
Beta blocker 28 (93.3%) 57 (96.6%) 0.541 20 (64.5%) 26 (78.8%) 0.252
Data are presented mean ± standard deviation or n (%).
ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blockers; BSA = body surface area; DBP = diastolic blood pressure;
HFpEF = heart failure patients with preserved ejection; HFrEF = heart failure patients with reduced ejection fraction; PASP = pulmonary artery
systolic pressure; RB = angiotensin receptor blocker; SBP = systolic blood pressure.
* p < 0.05.
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before opening of mitral valve while minimum
volume just before mitral valve closure). The
LAV emptying fraction was calculated as
follows
LAVemptying fraction¼f½ðmax:LAVmin:LAVÞ
=max:LAVg100Diastolic dysfunction assessment
A composite of mitral inflow peak E velocity to
peak A velocity ratio (E/A), mitral inflow deceler-
ation time (DT), and an average of the lateral
and medial mitral annular tissue Doppler veloci-
ties (E0) and (E/e0) ratio were used to grade dias-
tolic dysfunction as: (1) normal; (2) mild; (3)
moderate (impaired relaxation or pseudonormal
with moderate elevation of filling pressures); (4)
severe (advanced reduction in compliance); or (5)
indeterminate diastolic function.
Normal diastolic function included subjects with
septal E0P 8, lateral E0P 10, and LA volume
indexed <34 mL/m2. Those with one or more ele-
vated values for these variables were considered
abnormal, and additional measurements were
used to determine the grade of diastolic dysfunc-
tion. Mild diastolic dysfunction (Grade I) was clas-Please cite this article in press as: Roushdy A., Adel W., Independent pr
reduced versus preserved ejection fraction, J Saudi Heart Assoc (2016), httsified as a mitral E/A ratio <0.8, DT >200 ms, and
an E/e0 ratio <8. Moderate diastolic dysfunction
(Grade II) was classified as a mitral E/A ratio of
0.8–1.5, average E/e0 ratio of 9–12, and DT of 160–
200 ms. Severe diastolic dysfunction (Grade III)
was characterized by restrictive filling with an
E/A ratio P2, DT <160 ms, and average E/e0 ratio
>13 or septal E/e0 ratio P15 and lateral E/e0 ratio
>12. Participants were required to meet two Dop-
pler criteria for moderate or severe diastolic dys-
function to be so classified. Patients meeting one
criterion for moderate or severe diastolic dysfunc-
tion or those with borderline parameters were
classified as indeterminate rather than normal [8].
Mitral and tricuspid valve regurgitation
assessment [9]
Any degree of mitral regurgitation was docu-
mented and rheumatic etiology of mitral regurgi-
tation was excluded for all patients enrolled in
the study. Severity of mitral regurgitation was
determined according to the color flow jet area
and vena contracta according to the American
Society of Echocardiography recommendations
[9] where mild regurgitation has vena contracta
<0.3 cm and a regurgitant jet area <4 cm2, whereas
severe mitral regurgitation, had vena contracta
>0.7 cm and a regurgitant jet area >10 cm2. The
same recommendations were applied to gradeedictors of developing pulmonary hypertension in heart failure with
p://dx.doi.org/10.1016/j.jsha.2016.10.005
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area <5 cm2 was considered mild TR, those
between 5 cm2 and 10 cm2 are moderate while sev-
ere TR has an area >10 cm2.
Pulmonary artery systolic pressure assessment
Color flow guided continuous wave Doppler
was applied to determine the peak tricuspid
regurgitant velocity. The highest velocity obtained
from multiple views measured in meter per sec-
ond was used. Pulmonary artery systolic pressure
(PASP) was calculated using the equation:
PASP ¼ 4V2 þ RAP
where V = the maximal tricuspid regurgitation jet veloc-
ity, and RAP = right atrial pressure. RAP was deter-
mined according to the inferior vena cava diameter
and its collapsibility with inspiration.
Patients were considered to have PH based on
the intermediate or high echocardiographic prob-
ability of PH stated in the European Society of
Cardiology and the European Respiratory Society
guidelines for the diagnosis and treatment of PH
[10]. Intermediate echocardiographic probability
of PH was considered with peak velocity of TR
ranging from 2.9 m/s to 3.4 m/s, whereas high
probability of PH was considered with peak veloc-
ity of TR > 3.4 m/s [10].
2.4. Statistical analysis
All data were gathered, tabulated, and statisti-
cally analyzed on a PC using a commercially avail-Table 2. Independent sample t test between heart failure patients w
artery systolic pressure (PASP; Group1A) and those with pul
echocardiographic parameters measured.
Variables HFrEF patients
Group 1A (normal PASP) G
LV ESD 4.29 ± 0.69 4
LV EDD 5.94 ± 0.63 6
LV FS 27.91 ± 5.87 2
LV EF (M-mode) 52.84 ± 8.94 4
LV EDV 108.12 ± 40.46 1
LV ESV 63.93 ± 26.07 9
LV EF (SIM) 42.43 ± 6.95 3
LAD 3.99 ± 0.45 4
LAA 21.03 ± 14.99 2
LAV 51.47 ± 18.98 7
LAV/BSA 27.02 ± 10.13 4
LAVEF 37.94 ± 12.32 3
E/A 0.87 ± 0.46 1
DT 250.00 ± 50.90 2
E0 0.078 ± 0.02 0
E/e0 8.26 ± 2.57 8
Data are presented as mean ± standard deviation.
BSA = body surface area; DT = deceleration time; EDD = end diastolic diame
tolic diameter; ESV = end systolic volume; FS = fractional shortening; LAA
LAVEF = left atrial volume emptying fraction; SIM = Simpson’s model.
Please cite this article in press as: Roushdy A., Adel W., Independent pr
reduced versus preserved ejection fraction, J Saudi Heart Assoc (2016), httable statistical software package MedCalc version
11.6.1.0 (MedCalc Software, Mariakerke, Belgium).
Qualitative variables are expressed as frequency
and percentage and compared using chi-squared
test. Quantitative variables are expressed as
mean ± standard deviation and assessed using
independent sample t test. Multivariate analysis
was done using multiple regression with step-
wise approach. Only significant variables in the
univariate analysis were entered in the multivari-
ate analysis model. A p value was considered sig-
nificant if <0.05 and p < 0.01 was considered highly
significant.3. Results
The study included a total of 153 patients who
were divided into two groups; Group 1 included
89 patients with HFrEF and Group 2 included 64
patients with HFpEF.3.1. Evaluation of HFrEF patients
Eighty-nine patients with HFrEF were subdi-
vided into two subgroups according to the pres-
ence of PH; Group 1A with normal PASP (mean
PASP of 21.05 ± 7.69 mmHg; n = 30) and Group
1B with PH (mean PASP of 43.9 ± 4.95 mmHg;
n = 59). There was no significant difference
between the two subgroups regarding demo-
graphic and clinical characteristics with the excep-
tion of systolic BP (p = 0.035), presence of diabetesith reduced ejection fraction (HFrEF) with normal pulmonary
monary hypertension (Group 1B) with regard to different
Independent sample t test
roup 1B (PH) t p
.90 ± 0.79 2.986 0.004
.31 ± 0.68 2.098 0.04
2.32 ± 5.67 3.703 0.0004
3.36 ± 8.99 3.999 0.0001
40.65 ± 52.37 2.476 0.015
0.56 ± 40.39 3.344 0.002
6.66 ± 7.92 2.839 0.006
.53 ± 0.34 5.555 <0.0001
2.59 ± 3.75 0.449 0.66
9.11 ± 23.00 4.739 <0.0001
0.64 ± 11.67 4.560 <0.0001
5.15 ± 12.61 0.843 0.40
.37 ± 1.06 2.889 0.005
05.17 ± 57.05 3.114 0.003
.10 ± 0.10 1.616 0.11
.92 ± 3.82 0.718 0.47
ter; EDV = end diastolic volume; EF = ejection fraction; ESD = end sys-
= left atrial area; LAD = left atrial diameter; LAV = left atrial volume;
edictors of developing pulmonary hypertension in heart failure with
p://dx.doi.org/10.1016/j.jsha.2016.10.005
Fig. 1. Comparison between the normal pulmonary pressure subgroup and the pulmonary hypertensive subgroup in (A) heart failure patients
with reduced ejection fraction and (B) heart failure patients with preserved ejection fraction patients with regard to diastolic function.
DD = diastolic dysfunction; HFpEF = heart failure preserved ejection fraction; HFrEF = heart failure reduced ejection fraction; PAP = pulmonary
artery pressure; PHT = pulmonary hypertension.
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PULMONARY HYPERTENSION IN HEART FAILURE(p = 0.04), presence of dyslipidemia (p = 0.005), and
diuretics usage (p = 0.003; Table 1).
Univariate analysis of the echocardiographic
parameters showed significant differences
between the two subgroups with regard to all LV
parameters, LAD, LAV, LAV indexed to body sur-
face area, E/A ratio, and DT, whereas the differ-
ences regarding LAA, LAV emptying fraction, e0,
or the E/e0 ratio were not significant (Table 2).
There was no significant difference with regard
to diastolic function grading, 14 patients (46.6%)
in Group 1A and 31 patients (52.5%) in Group 1B
had normal diastolic function while 16 patients
in Group 1A and 28 patients in Group 1B had dif-
ferent grades of diastolic dysfunction (Fig. 1).
There was significant difference between the
two subgroups with regard to mitral regurgitation
grading, whereas 94.9% of the PH patients (Group
1B) had mild (n = 40) or moderate (n = 16) mitral
regurgitation compared to 83.3% of patients withPlease cite this article in press as: Roushdy A., Adel W., Independent pr
reduced versus preserved ejection fraction, J Saudi Heart Assoc (2016), httnormal PASP (Group 1A) who had mild or moder-
ate mitral regurgitation (p = 0.04; Fig. 2). There was
also significant difference between the two sub-
groups with regard to TR severity, whereas most
of the patients with normal PASP had mild TR
and most of the patients with PH had moderate
TR; seven patients in this group had severe TR
(p < 0.001; Fig. 3).
On the basis of the data obtained from the uni-
variate analysis, multiple regression was used to
establish a multivariate model for the develop-
ment of PH. In this multivariate model, the pres-
ence of diabetes (p = 0.04), diuretics usage
(p = 0.04), LAV (p = 0.007), and TR grade
(p < 0.001) were significant independent predic-
tors for the development of PH among patients
with HFrEF. The overall significance of the model
was highly significant with p < 0.001, the coeffi-
cient of determination (R2) was 0.69 and the multi-
ple correlation coefficient was 0.83.edictors of developing pulmonary hypertension in heart failure with
p://dx.doi.org/10.1016/j.jsha.2016.10.005
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Fig. 2. Comparison between the normal pulmonary pressure subgroup and the pulmonary hypertensive subgroup in (A) heart failure patients
with reduced ejection fraction and (B) heart failure patients with preserved ejection fraction with regard to mitral regurgitation grade.
HFpEF = heart failure preserved ejection fraction; HFrEF = heart failure reduced ejection fraction; PAP = pulmonary artery pressure;
PHT = pulmonary hypertension; MR = mitral regurgitation.
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Sixty-four patients with HFpEF were subdivided
into Group 2A with normal PASP
(22.62 ± 6.16 mmHg; n = 31) and Group 2B with
PH (40.7 ± 2.95 mmHg; n = 33). There was no sig-
nificant difference between the two subgroups
regarding demographic and clinical characteristics
with the exception of presence of hypertension,
which was present in 90.9% of patients in Group
2B compared to 64.5% of patients in Group 2A
(p = 0.02), and diuretics usage where 72.7% of
Group 2B patients used diuretics compared to
22.5% of Group 2A patients (p = 0.009; Table 1).
Univariate analysis of the different echocardio-
graphic parameters showed no significant differ-
ence between the two subgroups with regard to
LV systolic or diastolic function parameters. Con-
cerning the LA measurements there was signifi-
cant difference regarding LAD and LAA (p = 0.02
and 0.015 respectively) (Table 3).Please cite this article in press as: Roushdy A., Adel W., Independent pr
reduced versus preserved ejection fraction, J Saudi Heart Assoc (2016), httThere was no significant difference in diastolic
function grading, 28 patients (90.3%) in Group
2A and 24 patients (72.7%) in Group 2B had mild
Grade I diastolic dysfunction (Fig. 1).
Mitral regurgitation grade differed significantly
between the two subgroups whereas 72.2% of
patients in Group 2B had mild (n = 15) and moder-
ate (n = 9) mitral regurgitation compared to 51.6%
of patients in Group 2A who had mild or moderate
mitral regurgitation (p = 0.05; Fig. 2). There was
also significant difference between the two sub-
groups with regard to TR severity, whereas most
of the patients with normal PASP had mild TR
and most of the patients with PH had moderate
TR (p < 0.0001; Fig. 3).
Using multiple regression analysis, only diuret-
ics usage (p = 0.02) and TR grade (p < 0.0001) were
found to be significant independent predictors for
development of PH. The overall significance of the
model was highly significant with p < 0.001, theedictors of developing pulmonary hypertension in heart failure with
p://dx.doi.org/10.1016/j.jsha.2016.10.005
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Fig. 3. Comparison between the normal pulmonary pressure subgroup and the pulmonary hypertensive subgroup in (A) heart failure patients
with reduced ejection fraction and (B) heart failure patients with preserved ejection fraction with regard to tricuspid regurgitation grade.
HFpEF = heart failure preserved ejection fraction; HFrEF = heart failure reduced ejection fraction; PAP = pulmonary artery pressure;
PHT = pulmonary hypertension; TR = tricuspid regurgitation.
J Saudi Heart Assoc
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PULMONARY HYPERTENSION IN HEART FAILUREcoefficient of determination (R2) was 0.59 and the
multiple correlation coefficient was 0.76.4. Discussion
PH secondary to left heart disease is a common
complication especially to HF with preserved or
reduced EF; when present it results in more sev-
ere symptoms and more exercise intolerance
[11]. We sought to compare the different predic-
tors of PH in patients with HFrEF versus patients
with HFpEF. To the best of our knowledge this is
the first study to compare PH in HFrEF versus
HFpEF. This study is also characteristic in utilizing
the intermediate or high echocardiographic prob-
ability of PH stated in the European Society of
Cardiology and the European Respiratory Society
guidelines for the diagnosis and treatment of PH
as a differentiating point between patients with
normal PASP and those with PH [10]. Thus, thePlease cite this article in press as: Roushdy A., Adel W., Independent pr
reduced versus preserved ejection fraction, J Saudi Heart Assoc (2016), httstudy is not concerned with the presence or
absence of any degree of PH but is mainly con-
cerned with the development of PH. We sought
this using a low threshold for PH, which will help
to establish early diagnoses for patients at high
risk of developing progressive PH in the future.
Also, the independent predictors for PH in this
study were not only limited to the causal determi-
nants but also included other variables that could
act as warning signs to alert the treating physician
to follow-up HF patients accurately for the devel-
opment of PH.
PH was present in 66.3% of patients with HFrEF
and 51.5% of patients with HFpEF. This was in
agreement with earlier studies that stated that
PH ranged from 33% to 83% in HF patients [12,13].
In the current study, there was significant differ-
ence between HFrEF patients with normal PASP
and those with mild PH with regard to LV dimen-
sions, volumes, and EF. This difference was stilledictors of developing pulmonary hypertension in heart failure with
p://dx.doi.org/10.1016/j.jsha.2016.10.005
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Table 3. Independent sample t test between heart failure patients with preserved ejection fraction (HFpEF) with normal pulmonary
artery systolic pressure (PASP; Group 2A) and those with pulmonary hypertension (Group 2B) with regard to different
echocardiographic parameters measured.
Variables HFpEF patients Independent sample t test
Group 2A (normal PASP) Group 2B (PH) t p
ESD 3.56 ± 0.46 3.50 ± 0.44 0.382 0.70
EDD 5.44 ± 0.44 5.30 ± 0.42 0.909 0.37
FS 35.09 ± 4.21 33.99 ± 4.85 0.715 0.48
EF (M-mode) 63.76 ± 5.55 61.56 ± 5.57 1.127 0.27
EDV 30.19 ± 11.12 33.38 ± 9.42 0.849 0.40
ESV 72.85 ± 21.03 76.79 ± 17.21 0.554 0.58
EF (SIM) 58.35 ± 5.30 57.90 ± 4.80 0.250 0.80
LAD 3.92 ± 0.38 4.29 ± 0.58 2.408 0.02
LAA 16.03 ± 3.84 19.90 ± 5.60 2.542 0.015
LAV 47.50 ± 16.26 64.94 ± 27.12 2.009 0.066
LAV/BSA 24.77 ± 8.25 33.54 ± 13.77 1.989 0.07
LAVEF 47.44 ± 11.81 39.46 ± 13.42 1.858 0.07
E/A 0.81 ± 0.31 1.09 ± 0.52 1.679 0.12
DT 254.19 ± 50.99 238.00 ± 34.73 0.972 0.34
E0 0.088 ± 0.02 0.10 ± 0.03 0.989 0.33
E/e0 7.43 ± 3.52 7.60 ± 2.63 0.147 0.88
Data are presented as mean ± standard deviation.
BSA = body surface area; DT = deceleration time; EDD = end diastolic diameter; EDV = end diastolic volume; EF = ejection fraction; ESD = end sys-
tolic diameter; ESV = end systolic volume; FS = fractional shortening; LAA = left atrial area; LAD = left atrial diameter; LAV = left atrial volume;
LAVEF = left atrial volume emptying fraction; SIM = Simpson’s model.
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degree of mitral regurgitation. Miller et al. [14]
found that elevated PASP complicating chronic
systolic HF had lower EF and DT and higher
degree of functional mitral regurgitation. Never-
theless, these parameters were not independent
predictors of PH in HFrEF patients in our study;
this was partly in agreement with Enriquez-
Sarano et al. [15], who found that DT and the
effective regurgitant orifice area of mitral regurgi-
tation but not EF or end systolic volume were
independent predictors of PH in LV dysfunction.
An association between the severity of LV dias-
tolic dysfunction and increasing PASP has been
shown previously [16]. However, there was no sig-
nificant difference between the two subgroups in
the current study with regard to diastolic function
grading. We assume that this finding could be
related to the low threshold of PH used in the cur-
rent study and to the fact that most of the patients
in both subgroups had mild degree of diastolic
dysfunction.
There was significant difference between the
two subgroups with regard to LAD, LAV, and
LAV indexed to body surface area. LA size and
function has been actively studied as a predictor
of many adverse cardiovascular outcomes [17,18]
These LA parameters are believed not only to
measure the left atrium but also to act as a surro-
gate for either diastolic dysfunction or degree of
mitral regurgitation or both and thus have theirPlease cite this article in press as: Roushdy A., Adel W., Independent pr
reduced versus preserved ejection fraction, J Saudi Heart Assoc (2016), httrole in the pathogenesis of PH in left heart
disease.
Also, there was significant difference with
regard to TR with Group 1B showing increase in
the severity of TR compared to Group 1A.
Although TR severity varies among patients with
comparable degrees of PH and right ventricular
remodeling, tricuspid leaflet area is usually
increased in PH and the adequacy of this increase
determines TR severity [19].
The presence of diabetes (p = 0.04), diuretics
usage (p = 0.04), LAV (p = 0.007), and TR grade
(p < 0.001) were significant independent predic-
tors for the development of PH among patients
with HFrEF. In agreement with our results, Hans-
mann et al. [20] showed that PH is linked to insu-
lin resistance and other authors suggested that
insulin resistance can act as a novel disease mod-
ifier in PH [21,22]. In an editorial focus published
nearly a decade ago, the author stated that
‘‘Whether the increase in diabetes will be associ-
ated with an (delayed) increase in PH over the
next few years and decades is not clear, but
remains a possibility’’ [23].
Tumminello et al. [24] also stated that LAV act as
independent predictor of PASP in HF patients at
rest. PASP is known also to be a strong determi-
nant of TR severity among other factors as stated
byMutlak et al. [25]. The increased use of diuretics
in patients with increasing PASP perhaps repre-
sent a marker of disease presence where theedictors of developing pulmonary hypertension in heart failure with
p://dx.doi.org/10.1016/j.jsha.2016.10.005
FU
LL
 L
EN
G
TH
 A
RT
IC
LE
J Saudi Heart Assoc
2016;xxx:xxx–xxx
ROUSHDY, ADEL 9
PULMONARY HYPERTENSION IN HEART FAILUREincreased pulmonary venous congestion and PH
is relieved by decongesting the lungs through
diuretics and thus an increased compliance of
these patients to diuretics is seen.
Concerning the HFpEF group, there was no sig-
nificant difference concerning diastolic dysfunc-
tion grading between the two subgroups, which
may indicate precipitating factors for PH other
than diastolic dysfunction itself, especially in the
early phase of PH. There was significant differ-
ence between the two subgroups with regard to
presence of hypertension (p = 0.02), and diuretics
usage (p = 0.009). The increased usage of diuretics
in the PH subgroup may be due to the role of
diuretics in reducing PH through a reduction in
left-sided filling pressures [10]. Concerning LA
measurements, there was significant difference
between the two subgroups with regard to LAD
and LAA. According to Thenappan et al. [26] the
presence of hypertension as well as left atrial
enlargement among other factors best differenti-
ated PH in HFpEF from PH alone or normal
controls.
There was significant difference between
patients in the HFpEF subgroups with regard to
severity of both mitral regurgitation and TR with
more patients having higher grade of mitral regur-
gitation and TR in the PH subgroup. This is
believed to be related to the fact that mitral regur-
gitation plays a role in the development of PH [27],
whereas TR is a reflection of severity of this PH.
This was in agreement with recent studies that
concluded that TR progression was associated
with worsening PH [28,29].
In the current study, only diuretics usage
(p = 0.02) and TR grade (p < 0.0001) were signifi-
cant independent predictors for evolving PH
among patients with HFpEF. This was in agree-
ment with earlier studies that showed that TR
velocity was an independent predictor of
exercise-induced PH in patients with normal left
ventricular systolic function [30]. Lam et al. [12]
hypothesized that PH would be related to the
development and severity of clinically significant
pulmonary congestion, thus distinguishing HFpEF
from preclinical hypertensive heart disease with-
out overt HF. In this context, the significant
increase in diuretic usage among HFpEF patients
in the PH subgroup could be explained.
4.1. Study limitations and recommendations
Many studies have tried to determine indepen-
dent predictors of PH among HF patients. The
diversity of the results of these studies is mainly
due to the different definitions of PH used as wellPlease cite this article in press as: Roushdy A., Adel W., Independent pr
reduced versus preserved ejection fraction, J Saudi Heart Assoc (2016), httas the different predictors studied. As the current
study is unique in applying low threshold for the
development of PH in heart failure patients, it
showed disagreement with number of earlier
studies who studied predictors for the develop-
ment of higher degrees of PH and thus our
hypothesis is that different predictors affect differ-
ent degrees of PH. Also the predictive value of the
parameters studied for subsequent progression of
PH would require a long-term follow-up study,
which is being prepared.
The role of diabetes in the development of PH in
HFrEF patients should be further evaluated by
using different biochemical markers to determine
if the mere presence of diabetes, its duration, the
levels of control of blood sugar, or all these factors
contribute to PH among HF patients. Establishing
different cut-off points for biochemical markers
for diabetes and relating these cut-off points to
the development of PH is currently an area of
active research in our institute.5. Conclusion
PH is an important cause of increased morbidity
and mortality among HF patients. The early detec-
tion of PH among these patients would allow for
proper patient care and careful follow-up, thus
reducing both morbidity and mortality by apply-
ing targeted therapies suitable for these patients.
In the mild degree of PH neither the decrease in
EF among HFrEF patients nor the diastolic dys-
function grade in HFpEF patients act as indepen-
dent predictors for evolving PH. Common
independent predictors for evolving PH in both
HFrEF and HFpEF patients are the increased
severity of TR and increased use of diuretics.
Other independent predictors present in HFrEF
and not in HFpEF patients are the presence of dia-
betes and increased LAV.Conflict of interest
All authors have no conflicts of interest to
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